Abstract：Objective To investigate relationship of single nucleotide polymorphism (SNP）at rs5029924 locus in A20 promoter region and posttraumatic sepsis. Methods PCR-DNA sequencing was used to analyze different gene distribution at rs5029924 locus of 103 trauma patients with sepsis (Group A), 120 trauma patients without sepsis (Group B) and 135 healthy peoples (control group). Relation of different genotypes at rs5029924 locus to sepsis susceptibility was analyzed. Peripheral blood cells of healthy peoples of different genotypes were stimulated using lipopolysaccharides (LPS) in vitro. Expression of A20 mRNA was measured by fluorescent quantitative PCR, expression of A20 protein by flow cytometry, and levels of TNF-α and IL-1β by ELISA method. Results Frequency of rs5029924 genotypes CC, CT and TT was respective 77.8%, 20.0% and 2.2% in control group; 63.1%, 34.0% and 2.9% in Group A； 83.3%, 15.0% and 1.7% in Group B. Significantly lower frequency of CC genotype was observed in Group A when compared to Group B and control group (P<0.05), but no statistical differences were recorded between Group B and control group (P>0.05). CT/TT genotype increased risk coefficient of sepsis to 2.397-fold higher level when compared to CC genotype. Allele T increased prevalence of sepsis significantly as well (OR=2.056) when compared to allele C. After LPS treatment in vitro, CC genotype individuals revealed significantly higher levels of A20 mRNA and protein in peripheral blood leukocytes, but significantly lower levels of TNF-α and IL-1β when compared to CT/TT genotype individuals. Conclusion Polymorphism of rs5029924 locus is associated with sepsis susceptibility and the reason may be that mutant genes affect promoter activity and down-regulate A20 expression, which fails to suppress inflammation.
［1］Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med, 2003, 31(4):1250-1256.
［5］Wertz IE, O’Rourke KM, Zhou H, et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature, 2004, 430(7000):694-699.
［6］Ma KK, Banas K, de Bold AJ. Determinants of inducible brain natriuretic peptide promoter activity. Regul Pept, 2005, 128(3):169-176.
［7］Baker SP, O’Neill B, Haddon W Jr, et al. The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma, 1974, 14(3):187-196.
［8］Gu W, Shan YA, Zhou J, et al. Functional significance of gene polymorphisms in the promoter of myeloid differentiation-2. Ann Surg, 2007, 246(1):151-158.
［9］Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)）Method. Methods, 2001, 25(4):402-408.
［10］Mauro C, Pacifico F, Lavorgna A, et al. ABIN-1 binds to NEMO/IKKgamma and co-operates with A20 in inhibiting NF-kappaB. J Biol Chem, 2006, 281(27):18482-18488.
［11］Boone DL, Turer EE, Lee EG, et al. Corrigendum: The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol, 2004, 5(10):1052-1060.
［12］Lee EG，Boone DL，Chai S，et al. Failure to regulate TNF-αinduced NF-κB and cell death responses in A20 deficient mice. Science, 2000, 289(5488):2350-2354.
［14］Musone SL, Taylor KE, Nititham J, et al. Sequencing of TNFAIP3 and association of variants with multiple autoimmune diseases. Genes Immun, 2011, 12(3):176-182.
［15］Musone SL, Taylor KE, Lu TT, et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nature Genet, 2008, 40(9):1062-1064.
［16］Dieguez-Gonzalez R, Calaza M, Perez-Pampin E, et al. Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-kappaB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility. Arthritis Res Ther, 2009, 11(2):R42.
［17］Cormier C, Bossé Y, Mfuna L, et al. Polymorphisms in the tumour necrosis factor alpha-induced protein 3 (TNFAIP3）gene are associated with chronic rhino sinusitis. J Otolaryngol Head Neck Surg, 2009, 38(1):133-141.
［18］Paskulin DD, Fallavena PR, Paludo FJ, et al. TNF -308G > a promoter polymorphism (rs1800629）and outcome from critical illness. Braz J Infect Dis, 2011, 15(3):231-238.
［19］Stassen NA, Breit CM, Norfleet LA, et al. IL-18 promoter polymorphisms correlate with the development of post-injury sepsis. Surgery, 2003, 134(2):351-356.
